Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

The dawning era of personalized medicine exposes a gap in medical education.

Salari K.

PLoS Med. 2009 Aug;6(8):e1000138. doi: 10.1371/journal.pmed.1000138. Epub 2009 Aug 25. No abstract available.

2.

Effect of genetic testing for risk of Alzheimer's disease.

Kane RA, Kane RL.

N Engl J Med. 2009 Jul 16;361(3):298-9. doi: 10.1056/NEJMe0903449. No abstract available.

PMID:
19605835
3.

Disclosure of APOE genotype for risk of Alzheimer's disease.

Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA; REVEAL Study Group.

N Engl J Med. 2009 Jul 16;361(3):245-54. doi: 10.1056/NEJMoa0809578.

4.

Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study.

Sanderson SC, O'Neill SC, White DB, Bepler G, Bastian L, Lipkus IM, McBride CM.

Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1953-61. doi: 10.1158/1055-9965.EPI-08-0620. Epub 2009 Jun 30.

5.

Clinical use of pharmacogenomic tests in 2009.

Sheffield LJ, Phillimore HE.

Clin Biochem Rev. 2009 May;30(2):55-65.

6.

Direct-to-consumer genetic testing: two sides of the coin.

Farkas DH, Holland CA.

J Mol Diagn. 2009 Jul;11(4):263-5. doi: 10.2353/jmoldx.2009.090034. Epub 2009 Jun 18. No abstract available.

7.

Retention of medical genetics knowledge and skills by medical students.

Greb AE, Brennan S, McParlane L, Page R, Bridge PD.

Genet Med. 2009 May;11(5):365-70. doi: 10.1097/GIM.0b013e31819c6b2d.

PMID:
19452622
8.

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.

Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA.

J Gen Intern Med. 2009 May;24(5):656-64. doi: 10.1007/s11606-009-0949-1. Epub 2009 Mar 21. Review. Erratum in: J Gen Intern Med. 2009 Dec;24(12):1358.

9.

Is there a personal doctor in the house?

Bindman AB.

Ann Intern Med. 2009 Mar 3;150(5):351-2. No abstract available.

PMID:
19258561
10.

Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation?

Eckman MH, Greenberg SM, Rosand J.

J Gen Intern Med. 2009 May;24(5):543-9. doi: 10.1007/s11606-009-0927-7. Epub 2009 Mar 3.

11.

Pharmacogenetics--tailoring treatment for the outliers.

Woodcock J, Lesko LJ.

N Engl J Med. 2009 Feb 19;360(8):811-3. doi: 10.1056/NEJMe0810630. No abstract available.

PMID:
19228625
12.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA.

N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. Erratum in: N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text.

13.

Collaborative genome-wide association studies of diverse diseases: programs of the NHGRI's office of population genomics.

Manolio TA.

Pharmacogenomics. 2009 Feb;10(2):235-41. doi: 10.2217/14622416.10.2.235. Review.

14.

Moving up the slippery slope: mandated genetic screening on Cyprus.

Cowan RS.

Am J Med Genet C Semin Med Genet. 2009 Feb 15;151C(1):95-103. doi: 10.1002/ajmg.c.30202.

PMID:
19170092
15.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Eckman MH, Rosand J, Greenberg SM, Gage BF.

Ann Intern Med. 2009 Jan 20;150(2):73-83.

PMID:
19153410
16.

Impact of communicating familial risk of diabetes on illness perceptions and self-reported behavioral outcomes: a randomized controlled trial.

Pijl M, Timmermans DR, Claassen L, Janssens AC, Nijpels G, Dekker JM, Marteau TM, Henneman L.

Diabetes Care. 2009 Apr;32(4):597-9. doi: 10.2337/dc08-1049. Epub 2009 Jan 8.

17.

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2009 Jan;11(1):66-73. doi: 10.1097/GIM.0b013e3181928f56.

18.

Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.

Lai-Goldman M, Faruki H.

Genet Med. 2008 Dec;10(12):874-8. doi: 10.1097/GIM.0b013e31818de71c. Review.

PMID:
19092439
19.

An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons.

McGuire AL, Burke W.

JAMA. 2008 Dec 10;300(22):2669-71. doi: 10.1001/jama.2008.803. No abstract available.

20.

Genetic mapping in human disease.

Altshuler D, Daly MJ, Lander ES.

Science. 2008 Nov 7;322(5903):881-8. doi: 10.1126/science.1156409. Review.

Supplemental Content

Support Center